Subcutaneous anifrolumab is superior to placebo in multiple systemic lupus erythematosus disease activity measures at 52 ...

AstraZeneca has hit what appears to be a minor speed bump in gaining clearance in the U.S. for its subcutaneous (SC) version of lupus treatment Saphnelo. | AstraZeneca will have to negotiate what ...

New Afrezza prescribing information outlines higher starting dose conversions for patients transitioning from mealtime ...

The FDA has approved a label update for an inhaled insulin indicated for adults with type 1 or type 2 diabetes, according to ...

Discover tips for managing swelling, redness, and pain at subcutaneous immunoglobulin (SCIg) infusion sites for primary ...

Subcutaneous Saphnelo may offer people with lupus more convenient dosing with efficacy similar to the approved infusion version of the therapy, data show.